Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Research analysts at Leerink Partnrs upped their FY2028 earnings per share estimates for shares of NewAmsterdam Pharma in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will earn $0.44 per share for the year, up from their previous estimate of $0.39. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($2.06) per share.

A number of other equities analysts have also recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma has a consensus rating of “Buy” and an average target price of $33.80.

NewAmsterdam Pharma Stock Up 6.5 %

NAMS stock opened at $24.12 on Friday. The company has a fifty day moving average price of $17.67 and a two-hundred day moving average price of $18.52. NewAmsterdam Pharma has a one year low of $8.64 and a one year high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.08. The company had revenue of $2.28 million for the quarter, compared to the consensus estimate of $2.20 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma in the second quarter valued at about $38,000. Sei Investments Co. raised its stake in NewAmsterdam Pharma by 49.1% in the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock valued at $472,000 after purchasing an additional 8,087 shares in the last quarter. Wolverine Asset Management LLC raised its stake in NewAmsterdam Pharma by 117.7% in the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock valued at $298,000 after purchasing an additional 8,394 shares in the last quarter. TimesSquare Capital Management LLC raised its stake in NewAmsterdam Pharma by 3.7% in the third quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company’s stock valued at $4,237,000 after purchasing an additional 9,160 shares in the last quarter. Finally, Rosalind Advisors Inc. acquired a new position in NewAmsterdam Pharma in the second quarter valued at about $194,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Insider Transactions at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 19.50% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.